Treatment of adenoviral keratoconjunctivitis with a combination of povidone‐iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study

Abstract

The combination of PVP-I 1.0% and dexamethasone 0.1% four times a day can reduce symptoms and expedite recovery in epidemic keratoconjunctivitis patients.

Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis

“…18 A study that used the adenovirus type 5/New Zealand rabbit ocular model showed that corticosteroids alone can increase viral replication and the duration of viral shedding. 19 However, results from the present study and others [14][15][16] suggest that PVP-I/dexamethasone does not increase or prolong viral shedding, with adenoviral eradication observed from day 3 through day 12 in our study. In addition, rapid adenoviral eradication and clinical resolution with PVP-I/dexamethasone should ensure that the…”

“…The results from our study are consistent with results from studies of different PVP-I/dexamethasone formulations. [13][14][15][16] A phase 2 pilot study (NCT01461954) conducted in Brazil has also investigated the safety and efficacy of PVP-I 0.6%/dexamethasone 0.1% compared with vehicle for the treatment of clinically suspected acute viral conjunctivitis, and showed trends toward efficacy; however, too few patients with confirmed adenoviral conjunctivitis were enrolled to deliver meaningful results.…”

“…15 More recently, in a randomized controlled trial of 74 patients with adenoviral keratoconjunctivitis, patients treated with PVP-I 1.0%/dexamethasone 0.1% experienced significantly faster improvement of clinical signs than control groups, with near-complete recovery in 5-7 days and almost-complete viral eradication (92% reduction) by the fifth day of treatment. 16 In this multicenter phase 2 randomized controlled study, we evaluated the efficacy and safety of an ophthalmic suspension of PVP-I 0.6% and dexamethasone 0.1% for the treatment of acute adenoviral conjunctivitis in adults.…”

<p>Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions</p>

“…This significant treatment challenge is alleviated with the addition of PVI. 92 In addition to the mentioned treatment benefits, combination PVI/dexamethasone ophthalmic formulation displayed a favorable safety profile and was well tolerated when administered for up to 14 days. 93 There was also no statistically significant effect on intraocular pressure, as is often associated with topical corticosteroid use.…”

“…52 When comparing PVI/dexamethasone combination treatment with that of dexamethasone alone, combination drops not only increase recovery but also, reduce the risk of development of SEIs more effectively than steroids alone. 92 It is well documented that sole topical corticosteroid therapy has the risk of increased viral replication and prolonged shedding, further delaying the resolution of active infection. This significant treatment challenge is alleviated with the addition of PVI.…”